The Developmental Therapeutic Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD) is involved in discovery and development of new therapeutic agents for treatment of cancer. One of the essential parts of this mission involves the manufacture and supply of dosage forms to support human clinical trials under NCI sponsorship or through investigator-initiated INDs. Molecules for development enter the system under various mechanisms such as the Drug Development Group (DDG) , Rapid Access to Intervention Development (RAID) , or Joint Development Committee (JDC) . The current contract provides the NCI with pharmaceutical development and production of oral and topical dosage forms for use in clinical trials, advanced Pharmacology, and IND-directed Toxicology testing.
